argenx SE (ARGX) Cash Flow Statement

Historically, the OCF/NI ratio was highly erratic, often exceeding 1.0 during loss-making periods due to large non-cash charges like stock-based compensation. The recent convergence towards a ratio slightly below 1.0 suggests that as the company becomes consistently profitable, the quality of earnings is improving, though the gap indicates ongoing working capital investments are consuming a portion of the cash generated.

The trajectory shows a clear inflection point in 2025, where FCF turned positive and has since scaled rapidly. This shift is driven by the massive revenue growth of VYVGART outpacing operating expenses and minimal capital expenditure requirements, validating the high-margin, asset-light biologic manufacturing model.

The persistent negative working capital adjustments, even as the company scales, imply that the operational cash cycle is lengthening. This is likely due to the need to build substantial inventory for new indication launches and the timing of large payments to contract manufacturing partners, which investors should monitor as a potential ongoing drag on cash conversion.

The absence of shareholder returns is typical for a high-growth biotech, but the scale of cash accumulation—over $3.5 billion as noted in company intelligence—raises questions about future allocation. The current strategy appears to be building a war chest for potential M&A or to weather any future competitive or regulatory headwinds, rather than returning capital.